You had searched for:
There were no results matching the query.
You can also browse the topics below to find what you are looking for.
Support Services
- Download the Prescription and Service Request Form (PSRF)
- Fax the completed form to Shared Solutions® at 1-844-257-6127
Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.
Pharmacokinetic profile that supports dosing only 4 times a year
Phase 1 study assessing Pharmacokinetic parameters1,2*
AJOVY was evaluated in a phase 1 study to assess pharmacokinetic parameters for both quarterly and monthly dosing in healthy volunteers1
Plasma concentrations of AJOVY were slightly higher at month 3 for quarterly dosing than at month 1 for monthly2
The relationship between pharmacokinetics and efficacy has not been established.
long half-life3
This should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY.
There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women.
AJOVY is a fully humanized monoclonal antibody
| Target | ligand |
| IgG isotype |
IgG2∆a3 |
This information should not be construed to imply any difference in safety, efficacy, or other clinical outcomes.
Mechanism of Action
Patients experiencing migraine have increased levels of CGRP, a neuropeptide present in both the central and peripheral nervous system.2,3
When CGRP binds to its receptor, a cascade of events results, which contribute to neurogenic inflammation associated with migraine pain.2
AJOVY selectively targets the CGRP ligand, which is believed to block this cascade of events, thereby preventing the activation of the trigeminal system.1,4
